Remove Competition Remove High Tech Remove Patents Remove Seed Funding
article thumbnail

Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes

Xconomy

Merck also saw some expected fruits of its 2014 big-ticket acquisition of Cubist Pharmaceuticals wither away this week, as the Supreme Court wouldn’t reverse a decision that shaved years off the patent life of the top-selling antibiotic daptomyicin (Cubicin). —When Merck (NYSE: MRK ) bought Cubist Pharmaceuticals for $9.5